A 73-Year-Old Male With Urothelial Carcinoma - Episode 6
Neeraj Agarwal, MD: We have seen exciting advances in the treatment of metastatic or locally advanced urothelial carcinoma. We saw the approval of 5 PD-1 axis inhibitors over the last 3 years in the second-line urothelial carcinoma setting, after disease progression following platinum-based chemotherapy. Then we saw avelumab get approved as frontline maintenance therapy, which dramatically improved the overall survival benefit. We also saw antibody-drug conjugates, or the conjugate enfortumab, garner FDA approval for patients who have had disease progression on earlier lines of therapies in metastatic urothelial carcinoma. In addition, we saw erdafitinib, a FGFR pathway inhibitor, become available for patients who have had disease progression on earlier lines of therapies and are harboring FGFR alterations and fusions. All this is just a start, in my opinion. We are going to be seeing more antibody-drug conjugates get approved. In my view, the data presented on sacituzumab, another antibody-drug conjugate, are very promising. Hopefully we’ll see this agent become available for patients with advanced urothelial carcinoma.
We are seeing combinations of immune checkpoint inhibitors with antibody-drug conjugates moving to frontline therapy in clinical trials. Overall, this is very exciting news for us, for our patients, and hopefully we will not have to tell our patients that the median survival is only 18 months when they see us with a diagnosis of metastatic urothelial carcinoma in the future. Hopefully we’ll keep them alive with good quality of life for years. We are only a few years away from that happening.
Transcript edited for clarity.
Case Overview: A 73-Year-Old Male With Urothelial Carcinoma